Role of PET‐CT in management of posttransplant lymphoproliferative disorder

Styczyński, Jan

doi:10.1002/pbc.26741

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PET/CT scan has been used in the diagnosis of pediatric malignancies and infections, data concerning the use of PET/CT in pediatric PTLD particularly in PHTx patients remains limited 14,15 . Together with established clinical, laboratory, and radiological markers, for example, EBV viral load, PET/CT can support the decision to stop or reduce treatment when there is complete metabolic response, thereby reducing the burden of treatment in this vulnerable population 16 . Larger prospective studies are required to define the role of PET/CT in pediatric PTLD.…”

Section: Resultsmentioning

confidence: 99%

“…14,15 Together with established clinical, laboratory, and radiological markers, for example, EBV viral load, PET/CT can support the decision to stop or reduce treatment when there is complete metabolic response, thereby reducing the burden of treatment in this vulnerable population. 16 Larger prospective studies are required to define the role of PET/CT in pediatric PTLD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and management roles of FDG PET/CT imaging in post‐transplant lympho‐proliferation in pediatric heart transplantation

Brown

Carapellucci

Oshrine

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

Background: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of pediatric heart transplant (PHTx). 18F-FDG PET/CT has been used to differentiate early lympho-proliferation from more advanced PTLD. We report our experience with PET/CT in the management of PTLD following PHTx. Methods: This was a retrospective study of 100 consecutive PHTx recipients at our institution between 2004 and 2018. Patients who underwent PET/CT or conventional CT scans to evaluate for PTLD or high Epstein-Barr viral load were included. Results: Males, eight females. Median age at transplant was 3.5 months (IQR = 1.5-27.5). Median age at PTLD diagnosis was 13.3 years (IQR = 9.2-16.1). Median time between transplant and PTLD diagnosis was 9.5 (IQR = 4.5-15) years. Induction agents were used in 12 patients (50%): Thymoglobulin (N = 9), anti-IL2 (N = 2), and Rituximab (N = 1). Eighteen patients (75%) had PET/CT, of whom 14 had 18FDG-avid PTLD. Six had conventional CT. Nineteen patients (79.2%) had diagnostic biopsy confirmation of PTLD, and 5 (20.8%) had excisional biopsies. Two patients had Hodgkin's lymphoma; nine had monomorphic PTLD; eight had polymorphic PTLD; five were classified as other. Nine patients had monomorphic PTLD, including seven with diffuse large cell lymphoma (DLBC) and one with T cell lymphoma. The majority (16/24) had multisite involvement at PTLD diagnosis, and PET/CT showed that 31.3% (5/16) had easily accessible subcutaneous nodes. Seventeen patients (overall survival 71%) underwent successful treatment without recurrence of PTLD. Of seven deaths (7/24, 29%), five had DLBC lymphoma, one had polymorphic PTLD and one had T-cell lymphoma. Conclusion:PET-CT allowed simultaneous anatomical and functional assessment of PTLD lesions, while guiding biopsy. In patients with multiple lesions, PET/CT revealed the most prominent and active lesions, improving diagnostic accuracy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Diagnostic and management roles of FDG PET/CT imaging in post‐transplant lympho‐proliferation in pediatric heart transplantation

Brown

Carapellucci

Oshrine

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…We thank Dr. Styczynski for his Letter to the Editor, regarding our paper titled, “Preliminary experience on the use of PET–CT in the management of pediatric post‐transplant lymphoproliferative disease (PTLD).” We note his expertise and appreciate his interest in our paper. We have read with interest his comments and the references quoted.…”

mentioning

confidence: 95%